2026-10-08T20:05:13.000Z · 17 days ago Xortx Therapeutics outlines anticipated clinical trial application for XRx-026
Oct 8, 2026, 4:00 PM EDT · 17 days ago XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
2026-09-18T12:15:36.000Z · 5 weeks ago Xortx Therapeutics announces planned FDA IND submission for XRx-026
Sep 18, 2026, 8:05 AM EDT · 5 weeks ago XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
2026-09-10T20:20:33.000Z · 6 weeks ago Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo
Sep 10, 2026, 4:05 PM EDT · 6 weeks ago XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
2026-08-28T11:10:20.000Z · 1 month ago Xortx Therapeutics terminates investor relations, marketing agreement
Aug 28, 2026, 7:00 AM EDT · 1 month ago XORTX Announces Termination and Postponement of Investor Relations Program
Jun 15, 2026, 7:00 AM EDT · 4 months ago XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
Jun 12, 2026, 5:00 PM EDT · 4 months ago XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
May 18, 2026, 11:20 AM EDT · 5 months ago E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
2026-05-14T19:08:33.000Z · 5 months ago Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
2026-04-21T12:45:47.000Z · 6 months ago Xortx Therapeutics meets Nasdaq continued listing requirements
2026-04-01T17:05:46.000Z · 6 months ago Xortx Therapeutics to effect 5-for-1 share consolidation on April 6
Mar 26, 2026, 6:00 PM EDT · 7 months ago XORTX Announces Results of Annual and Special Meeting of Shareholders
Mar 26, 2026, 4:32 PM EDT · 7 months ago XORTX Announces Change of Effective Date of Share Consolidation
2026-03-13T11:11:51.000Z · 7 months ago Xortx reports proxy firms recommend shareholders vote ‘FOR’ share consolidation
Mar 13, 2026, 7:00 AM EDT · 7 months ago XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
2025-10-21T12:20:49.000Z · 1 year ago Xortx Therapeutics prices 1.75M shares at 63c in registered direct offering
Oct 21, 2025, 8:00 AM EDT · 1 year ago XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
Oct 20, 2025, 8:34 PM EDT · 1 year ago XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
Oct 20, 2025, 6:45 PM EDT · 1 year ago XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
2025-10-17T11:05:16.000Z · 1 year ago Xortx to acquire Renal Anti-Fibrotic Therapeutic Program from Vectus for $3M
Oct 17, 2025, 7:00 AM EDT · 1 year ago XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
2025-09-03T11:11:43.000Z · 1 year ago Xortx Therapeutics initiates IND preparation for XORLO in gout program
Apr 17, 2025, 7:45 PM EDT · 1 year ago XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Dec 12, 2024, 9:17 AM EST · 1 year ago XORTX Announces Presentation at the Rare and Genetic Disease Summit
Oct 18, 2024, 4:00 PM EDT · 2 years ago XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
Sep 13, 2024, 7:00 AM EDT · 2 years ago XORTX Announces Results of Annual and Special Meeting of Shareholders
Sep 6, 2024, 5:30 PM EDT · 2 years ago XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
Sep 3, 2024, 12:30 PM EDT · 2 years ago Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
Aug 23, 2024, 7:00 AM EDT · 2 years ago XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
Aug 20, 2024, 7:00 AM EDT · 2 years ago XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
May 17, 2024, 7:00 AM EDT · 2 years ago XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
Apr 30, 2024, 1:54 PM EDT · 2 years ago XORTX Reprices Warrants Issued in Connection with Previous Private Placements
Mar 19, 2024, 5:00 AM EDT · 2 years ago XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
Mar 4, 2024, 7:00 AM EST · 2 years ago XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units
Feb 1, 2024, 8:46 PM EST · 2 years ago XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
Jan 3, 2024, 7:00 AM EST · 2 years ago XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease